NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1

United States Army Medical Research and Development Command (USAMRDC)

Status and phase

Completed

Phase 2

Phase 1

Conditions

Plasmodium Falciparum

Treatments

Biological: NMRC-MV-Ad-PfC, NMRC-M3V-Ad-PfCA

Biological: NMRC-M3V-Ad-PfCA

Study type

Interventional

Funder types

NETWORK

Other U.S. Federal agency

Identifiers

NCT00392015

S-15-25

HSRRB A-13453 (Other Identifier)

NMRC.2006.0001 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to determine whether a new investigational malaria vaccine is safe, well tolerated and effective against experimental exposure to malaria when given to healthy people with no previous exposure to malaria. The vaccine consists of a modified form of a relatively common virus, adenovirus, that has been rendered incapable of replicating itself and modified to deliver the malaria gene of interest to the body's cells allowing the cell to manufacture the protein encoded by the gene and present it to the body's immune system in a more natural and presumably effective way.

Full description

The vaccine, called NMRC-M3V-Ad-PfCA (key: NMRC + Multi-antigen Multi-stage, Malaria Vaccine + Adenovectored + P. falciparum CSP & AMA1 antigens), is a combination of two recombinant adenovirus-derived constructs (adenovectors), one expressing the pre-erythrocytic stage antigen circumsporozoite protein (CSP) and the other expressing the erythrocytic stage antigen Apical Membrane Antigen 1 (AMA1), both from the 3D7 strain of P. falciparum. The vector is an attenuated, replication-deficient adenovirus derived from wildtype serotype 5 adenovirus through the deletion of several genes. The vaccine is formulated in a buffered saline solution (Final Formulation Buffer = FFB).

This is a Phase 1/2a, randomized, open-label, dose-escalating trial of the NMRC-M3V-Ad-PfCA vaccine administered intramuscularly to healthy, malaria-naïve adult volunteers. All volunteers will be seronegative (< 1:500, by a luciferase-based neutralizing antibody assay; VRC, Bethesda) for adenovirus serotype 5. In the first part of the study (dose-escalation phase, Part A), 1 x 10^10 particle units (pu) per construct or 2 x 10^10 pu total will be administered to six volunteers as a single dose to assess safety, and 4 weeks later, 5 x 10^10 pu per construct or 1 x 10^11 pu total dose (five-fold dose escalation) will be administered to six additional volunteers. In the second part of the study (regimen-comparison phase, Part B), three regimens for administration will be compared: one dose, two doses administered ten days apart, and two doses administered 16 weeks apart. Separate groups will receive one dose of the individual components of the vaccine (NMRC-MV-Ad-PfC and NMRC-MV-Ad-PfA). Following immunization, volunteers participating in the regimen-comparison phase as well as several non-immunized control volunteers (serving as infectivity controls) will be challenged with P. falciparum sporozoites in order to assess vaccine efficacy against non-immunized controls challenged at the same time. The proposed design of the regimen-comparison phase will provide information to direct selection of an appropriate dosing regimen for subsequent studies, and will also indicate whether the two constituent antigens, when co-formulated, act synergistically, independently, or interfere with each other in the induction of antigen-specific immune responses and protective immunity.

Enrollment

59 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Between the ages of 18-50 (inclusive)
Negative results of HIV ELISA, HbSAg, anti-HCV antibody, and no other clinically significant abnormal laboratory results from screening.
Adenovirus serotype 5 (Ad5) titer <1:500
Able to provide written informed consent.
Complete an Assessment of Understanding and verbalize an understanding of any questions answered incorrectly.
In good general health without clinically significant medical history or physical exam abnormalities at screening.
Willing to continue immunogenicity and clinical follow-ups for one year and telephone or mail (electronic/U.S. Postal) contact as long term safety monitoring provision for an additional four years (totaling five years of participation; immunized volunteers only).
Male and female participants being immunized and female participants being challenged agree to use effective means of birth control (an FDA approved contraceptive, abstinence) between screening and 60 days following last clinical study visit or able to provide evidence of no reproductive capability.

Exclusion criteria

Have a history of malaria infection, exposure to malaria infection(i.e. you have been to an area that has malaria within the past two years),lived in a country with malaria for more than 5 years or receipt of certain candidate malaria vaccines
Known immune system disease
Known blood, heart, liver, kidney disease
At known significant risk for developing heart disease
A positive result on HIV testing at screening
A positive result on Hepatitis B or C testing at screening
Removal of your spleen
Taking medication that suppresses the immune system within 30 days of immunization.
Received or will be receiving another vaccine within 30 days of immunization
Received blood products (e.g. transfused with blood cells, platelets, plasma or serum) within 120 days of the immunization
Have had serious adverse reactions to other vaccines including hives, anaphylaxis, respiratory difficulty, tongue/mouth/neck/throat/body swelling or abdominal pain
Pregnant, breastfeeding, or planning to become pregnant during the next year
Plan to participate (or have participated in the last 30 days) in any other research study including an investigational drug or device
Unwilling or unable to participate/complete all study elements
Evidence of previous infection with adenovirus 5 or prior receipt of an adenovirus containing vaccine.